Gilead Sciences Less: allowances for chargebacks decreased by 21.6% to $661.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.8%, from $717.00M to $661.00M. Over 5 years (FY 2020 to FY 2025), Less: allowances for chargebacks shows an upward trend with a 8.8% CAGR.
other_accounts_receivable_chargebacks_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $625.00M | $591.00M | $671.00M | $642.00M | $640.00M | $514.00M | $549.00M | $634.00M | $665.00M | $638.00M | $679.00M | $693.00M | $672.00M | $722.00M | $759.00M | $717.00M | $696.00M | $762.00M | $843.00M | $661.00M |
| QoQ Change | — | -5.4% | +13.5% | -4.3% | -0.3% | -19.7% | +6.8% | +15.5% | +4.9% | -4.1% | +6.4% | +2.1% | -3.0% | +7.4% | +5.1% | -5.5% | -2.9% | +9.5% | +10.6% | -21.6% |
| YoY Change | — | — | — | — | +2.4% | -13.0% | -18.2% | -1.2% | +3.9% | +24.1% | +23.7% | +9.3% | +1.1% | +13.2% | +11.8% | +3.5% | +3.6% | +5.5% | +11.1% | -7.8% |